Back

HF-REVERT: efficacy and safety of the microRNA inhibitor CDR132L in patients with reduced left ventricular ejection fraction after myocardial infarction

10 May 2026 (13:51 - 14:00)
Organised by: Logo
Congress Presentation Part of: Hottest trials (2) Heart Failure with Reduced Ejection Fraction (HFrEF) HFA Premium Access Heart Failure 2026 Heart Failure Association (HFA)

About the speaker

Photo
Professor Johann Bauersachs

Hannover Medical School, Hannover (Germany)

9 More presentations in this session

Presentation thumbnail
Low-dose digoxin in heart failure
Professor D. van Veldhuisen (Groningen, NL)
Slides Video
Presentation thumbnail
Discussant review - DECISION: main study
Professor G. Filippatos (Athens, GR)
Slides Video
Presentation thumbnail
DECISION/DIGIT-HF/DIG study level meta analysis
Associate Professor K. Damman (Groningen, NL)
Slides Video
Presentation thumbnail
Discussant review - DECISION/DIGIT-HF/DIG Meta Analysis
Professor J. McMurray (Glasgow, GB)
Slides Video
Presentation thumbnail
Blinded withdrawal of digoxin or placebo
Professor P. Van Der Meer (Groningen, NL)
Slides Video

Access the full session

Session thumbnail
Hottest trials (2)
Video

The Event

Event poster

Heart Failure 2026

10 May 2026 13:51 CET
You may be interested in
thumbnail
Congress Presentation
Targeting non-coding MiRNA for prevention of heart failure
31 August 2025
thumbnail
Congress Session
Late-Breaking Trials - Pharmacological treatment I
22 May 2022
thumbnail
Congress Session
HFA Studio by ESC TV - Hot Science from Heart Failure 2026 - HF REVERT
11 May 2026
thumbnail
Congress Session
Smaller trials: cardiac function and remodelling
1 September 2024

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources